This trial will follow people who have had CAR-T therapy for 15 years to assess any delayed adverse effects, monitor for RCL, and assess long-term efficacy.
1 Primary · 5 Secondary · Reporting Duration: at M3 post treatment, M6, M9, M12 and every 6M up to year 5, yearly until year 15.
1400 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · N/A
Age Any Age · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: